SoftServ's capabilities include full stack software development; security, accessibility and disaster recovery audits; mobile app development; containerization; Scientist.com marketplace configurations; and more.
SoftServ was created by Scientist.com's acquisition of Notch8 in Dec 2021. That same year, Scientist.com purchased HealthEconomics.Com, the world's largest Connected Community for the Value, Evidence and Market Access industry; InsideScientific, an online marketing content creator for the life sciences; and BioPharmCatalyst, a research-based portal that provides key catalyst updates for publicly traded biotech companies.
Scientist.com operates online marketplaces for most of the world's top 30 pharmaceutical companies, 120+ biotech companies and the US National Institutes of Health. The award-winning digital research platform helps life scientists test more ideas in less time.
Scientist.com's mission is to empower and connect scientists worldwide.
The company's digital research platform combines a custom-built, cloud native technology stack with white-glove customer and scientific support to enable scientists to run more innovative experiments in less time and at lower cost.
Scientist.com leverages internally developed machine learning models to provide actionable insights that improve operational efficiency and effective research management.
Scientist.com connects researchers at the world's top pharmaceutical companies, biotechnology companies, and the US National Institutes of Health to the world's largest network of scientific research suppliers.
Affimed N.V. announces launch of AFM28 blood cancer trial
Cardiff Oncology doses first subject with onvansertib in Phase two ONSEMBLE trial
Kintor Pharmaceutical completes subject enrolment in phase three KX-826 clinical trial in China
FDA removes partial clinical hold on Blueprint Medicines' Phase 1/2 BLU-222 trial
CSL opens Massachusetts research and development centre
BJ Bioscience signs clinical trial collaboration and supply agreement with Merck
DermBiont Touts Phase 2 Trial Data Treating Seborrheic Keratosis with SM-020 Topical Gel